Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.
EP: 1.The Evolution of ALK+ NSCLC Care
EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3
EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC
EP: 5.Key Differences Among ALK Inhibitors
EP: 6.Navigating ALK Inhibitor Toxicities
Now Viewing
EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization
EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC
EP: 11.Education and Support After Progression ALK Inhibitors
EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy
Lorlatinib’s Unique Adverse Event Profile
Key Themes:
- Cognitive effects, hypercholesterolemia, and peripheral neuropathy with lorlatinib
- Impact of adverse events on treatment selection
- Monitoring and management of cholesterol levels
Notable Insights:
- Dr Dietrich discussed lorlatinib’s unique adverse event profile and its impact on treatment decisions
Dr Lovly outlined best practices for monitoring and managing lorlatinib-induced hypercholesterolemia
Related Videos
Related Content
